Современные подходы к лечению больных стромальными опухолями желудочно-кишечного тракта

1. Kawanowa K et al. Hum Pathol 2006; 37: 1527–35.
2. Agaimy A et al. Am J Surg Pathol 2007; 31: 113–20.
3. Kindblom LG, Remotti HE, Aldenborg F et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259–69.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466–78.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70–83.
6. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459–65.
7. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 (Suppl. 2): 1–29.
8. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17 (Suppl. 10): 280–6.
9. Mazur M, Clarke H. Am J Surg Path, 1983.
10. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–80.
11. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–10.
12. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813–25.
13. Heinrich MC, Corless CL, Demetri GD et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342–49.
14. Стилиди И.С., Никулин М.П. и др. Оперативное лечение больных с первичными гастроинтестинальными стромальными опухолями. РМЖ Онкология. 2010; 1 (2): 25–9.
15. Clary BM, Dematteo RP, Lewis JJ et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8: 290–9.
16. Tran T, Davila JA, El Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100: 162–8.
17. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastro intestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 2005; 103: 821–9.
18. Tryggvason G, Gislason HG, Magnusson MK et al. Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST Study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289–93.
19. Blackstein ME, Blay JY, Corless C et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20: 157–63.
20. Casali PG, Jost L, Reichardt P et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 64–7.
21. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma. Version 2. Fort Washington, Pa: National Comprehensive Cancer Network, 2009.
22. Hassan I, You YN, Shyyan R et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15: 52–9.
23. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898–905.
24. DeMatteo RP et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg 2000; 231: 51–8.
25. Ng EH et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68–77.
26. Heinrich MC, Griffith DJ, Druker BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925–32.
27. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097–104.
28. Dematteo RP, Owzar K, Antonescu CR et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the US Intergroup phase II trial ACOSOG Z9000. Paper presented at: 2008 Gastrointestinal Cancers Symposium 2008; Orlando, Fla: Abstr. 8.
29. Zhan WH. China Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. J Clin Oncol 2007; (Suppl. 25): Abstr. 10045.
30. European Organisation for Research and Treatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediate- or high-risk of relapse. Available at: http://www.cancer.gov/clinicaltrials/EORTC-62024. Accessed Sept. 2, 2009
31. Scandinavian Sarcoma Group. SSGXVIII/AIO study protocol. Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). Available at: http://clinicaltrials.gov/ct2/show/NCT00116935?intr=%22Imatinib%22&rank=1. Accessed Sept. 2, 2009
32. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–80.
33. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620–5.
34. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at 2 dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626–32.
35. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127–34.
36. Casali PG, Verweij J, Kotasek D et al. Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. Eur J Cancer 2005; 201 (Suppl. 3): Abstr. 711.
37. Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J. GIST Meta-Analysis Group (MetaGIST). Comparison of 2 doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a metaanalysis based on 1640 patients (pts). J Clin Oncol 2007; 25: Abstr. 10004.
38. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368: 1329–38.
39. Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol 2008; 34: 844–50.
40. Rock EP, Goodman V, Jiang JX et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107–13.
41. Andtbacka RH, Ng CS, Scaife CL et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14–24.
42. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692–703.
43. Heinrich M, Corless C, Blanke C, Demetri G, Joensuu H, Mehren M, McGreevey L, Wait C, Griffith D, Chen C-J, Haley A, Kiese B, Druker B, Roberts P, Eisenberg B, Singer S, Silberman S, Dimitrijevic S, Fletcher C, Fletcher J. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proceedings of ASCO 2002; 21 (2a): Abstr. 6.
44. Кравцов В.Г. Клинико-морфологическая, иммунологическая характеристика и критерии прогноза гастроинтестинальных стромальных опухолей. Автореф. дис. … канд. мед. наук. М., 2007.
45. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11 (5): 465–75.
46. Gold JS, Dematteo RP. Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. Ann Surg Oncol 2007; 14 (4): 1247–8.
47. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33 (5): 466–77.
48. Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Cesne AL. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13 (12): 1596–603.
49. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39 (10): 1411–9.
50. Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112 (3): 608–15.

Л.А.Вашакмадзе, В.М.Хомяков, И.В.Колобаев

Московский НИИ онкологии им. П.А.Герцена

________________________________________________

L.A.Vashakmadze, V.M.Khomyakov, I.V.Kolobaev